Home › Non-Small Cell Lung Cancer › Ohio › Akron
Pag-aaral pangklinika para sa Non-Small Cell Lung Cancer sa Akron, OH
Isang pag-aaral para sa Non-Small Cell Lung Cancer ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Akron. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Nagre-recruitPhase 3
- Cleveland Clinic Akron General, Akron
- Aultman Health Foundation, Canton · 21 mi ang layo
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Nagre-recruitPhase 3
- Aultman Health Foundation, Canton · 21 mi ang layo
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Nagre-recruitPhase 3
- Akron General Medical Center, Akron
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Nagre-recruitPhase 3
- Aultman North, North Canton · 15 mi ang layo
- Aultman Massillon, Massillon · 20 mi ang layo
- Aultman Orrville Hospital, Orrville · 21 mi ang layo
- at 2 pa
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Nagre-recruitPhase 3
- Research Site, Canton · 21 mi ang layo
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Nagre-recruitPhase 3
- Aultman Hospital, Canton · 21 mi ang layo
Pan-tumor MRD Study
Nagre-recruitObservasyonal na pag-aaral
- Gabrail Cancer Center, Canton · 21 mi ang layo
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Nagre-recruitPhase 2/3
- Gabrail Cancer Center Research, Canton · 21 mi ang layo
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
Nagre-recruitPhase 2
- Gabrail Cancer Center, Canton · 21 mi ang layo
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Nagre-recruitPhase 2/3
- Tricounty Hematology and Oncology - Massillon, Massillon · 20 mi ang layo
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
Nagre-recruitPhase 1/2
- Gabrail Cancer Center Research, Canton · 21 mi ang layo
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Nagre-recruitPhase 3
- Gabrail Cancer Center, Canton · 21 mi ang layo
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Nagre-recruitPhase 2
- Gabrail Cancer and Research Center, Canton · 21 mi ang layo
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Nagre-recruitPhase 2
- Cleveland Clinic Mercy Hospital, Canton · 21 mi ang layo
- Aultman Health Foundation, Canton · 21 mi ang layo
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Nagre-recruitPhase 2
- Aultman Health Foundation, Canton · 21 mi ang layo
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Nagre-recruitPhase 2
- Aultman Health Foundation, Canton · 21 mi ang layo
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Nagre-recruitPhase 2/3
- Aultman Health Foundation, Canton · 21 mi ang layo
GEMINI-NSCLC: NSCLC Biomarker Study
Nagre-recruitObservasyonal na pag-aaral
- Aultman Hospital, Canton · 21 mi ang layo
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Nagre-recruitPhase 1
- Gabrail Cancer & Research Center, Canton · 21 mi ang layo
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Nagre-recruitPhase 1/2
- Research Site 138, Canton · 21 mi ang layo
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
Nagre-recruitPhase 1/2
- Gabrail Cancer Center Research, Canton · 21 mi ang layo
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
Nagre-recruitPhase 1/2
- Gabrail Cancer Research Center, Canton · 21 mi ang layo
Pag-aaral para sa Non-Small Cell Lung Cancer sa ibang lungsod
- Houston, TX145 pag-aaral
- New York City, NY120 pag-aaral
- Arlington, VA104 pag-aaral
- Nashville, TN97 pag-aaral
- Boston, MA90 pag-aaral
- Los Angeles, CA87 pag-aaral
- St. Louis, MO73 pag-aaral
- Chicago, IL61 pag-aaral
- Baltimore, MD60 pag-aaral
- San Antonio, TX59 pag-aaral
- Columbus, OH56 pag-aaral
- Washington, DC55 pag-aaral
Iba pang pag-aaral sa Akron
- Kanser sa Baga16 pag-aaral
- Kanser (lahat ng uri)13 pag-aaral
- Kanser sa Suso13 pag-aaral
- Kanser sa Prostate9 pag-aaral
- Acute Myeloid Leukemia8 pag-aaral
- Melanoma8 pag-aaral
- Small Cell Lung Cancer8 pag-aaral
- Metastatic Cancer8 pag-aaral
- Colorectal Cancer8 pag-aaral
- Steatotic Liver Disease7 pag-aaral
- Kanser ng Endometrium6 pag-aaral
- Kanser sa Ovary6 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.